Next Article in Journal
Localization of Frog Virus 3 Conserved Viral Proteins 88R, 91R, and 94L
Next Article in Special Issue
Characterization of the Filovirus-Resistant Cell Line SH-SY5Y Reveals Redundant Role of Cell Surface Entry Factors
Previous Article in Journal
Meal for Two: Human Cytomegalovirus-Induced Activation of Cellular Metabolism
Previous Article in Special Issue
Ebola Virus Isolation Using Huh-7 Cells has Methodological Advantages and Similar Sensitivity to Isolation Using Other Cell Types and Suckling BALB/c Laboratory Mice
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessReview
Viruses 2019, 11(3), 274;

Ebola Virus Entry: From Molecular Characterization to Drug Discovery

Department of Molecular Medicine, University of Padova, IT-35121 Padova, Italy
Author to whom correspondence should be addressed.
Received: 20 February 2019 / Revised: 15 March 2019 / Accepted: 16 March 2019 / Published: 19 March 2019
(This article belongs to the Collection Advances in Ebolavirus, Marburgvirus, and Cuevavirus Research)
PDF [1865 KB, uploaded 19 March 2019]


Ebola Virus Disease (EVD) is one of the most lethal transmissible infections, characterized by a high fatality rate, and caused by a member of the Filoviridae family. The recent large outbreak of EVD in Western Africa (2013–2016) highlighted the worldwide threat represented by the disease and its impact on global public health and the economy. The development of highly needed anti-Ebola virus antivirals has been so far hampered by the shortage of tools to study their life cycle in vitro, allowing to screen for potential active compounds outside a biosafety level-4 (BSL-4) containment. Importantly, the development of surrogate models to study Ebola virus entry in a BSL-2 setting, such as viral pseudotypes and Ebola virus-like particles, tremendously boosted both our knowledge of the viral life cycle and the identification of promising antiviral compounds interfering with viral entry. In this context, the combination of such surrogate systems with large-scale small molecule compounds and haploid genetic screenings, as well as rational drug design and drug repurposing approaches will prove priceless in our quest for the development of a treatment for EVD. View Full-Text
Keywords: Ebola virus; Filoviridae; VSV; retroviral vectors; virus-like particles; pseudovirus; antivirals; small molecules; viral entry Ebola virus; Filoviridae; VSV; retroviral vectors; virus-like particles; pseudovirus; antivirals; small molecules; viral entry

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Salata, C.; Calistri, A.; Alvisi, G.; Celestino, M.; Parolin, C.; Palù, G. Ebola Virus Entry: From Molecular Characterization to Drug Discovery. Viruses 2019, 11, 274.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top